Dr Begley is inaugural CEO of BioCurate, an initiative of Monash and Melbourne Universities to achieve impact from their biomedical research. He is a medical oncologist/hematologist, has a Ph.D. in cell and molecular biology, and extensive clinical and research experience. He served as Chief Scientific Officer at Akriveia Therapeutics, now Xilio, (California; 2016-2017), Chief Scientific Officer at TetraLogic Pharmaceuticals (Pennsylvania; 2012-2016), and Non-Executive Director Oxford BioTherapeutics (Oxford; 2012-2017). He was Vice-President and Global Head of Hematology/Oncology Research at Amgen (California; 2002-2012) where he was responsible for their 5 research sites. His group generated over 25 clinical-stage molecules including first-in-class bi-specific T-cell engager (BiTE) blinatumomab, and first approved oncolytic virus talimogene laherparepvec (T-Vec). He has also highlighted the issue of research integrity and scientific reproducibility and presented on this subject to President Obama's Science Council, the White House, US National Institutes of Health, US Academies of Science, US National Institute of Standards and Technology, the Wellcome Trust, and NHMRC. He has published over 200 papers (>25,000 citations; h-index 77; i10-index 188, source Google Scholar, October 2020). In addition, his TED-x seminar "The Complex Biology of Cancer" has >100,000 views. His honors include being elected first Foreign Fellow to the American Society of Clinical Investigation (2000), to the Association of American Physicians (2008), the Research "Hall of Fame" at his alma mater, the Royal Melbourne Hospital (2014), and to the Australian Academy of Health and Medical Sciences (2014).